Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Leukemia, Myeloid, Acute 51Leukemia 26Myelodysplastic Syndromes 10Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 9Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Congenital Abnormalities 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Blast Crisis 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Leukemia, Promyelocytic, Acute 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Liver Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Leukemia, Basophilic, Acute 3Carcinoma, Hepatocellular 3Myeloproliferative Disorders 2Lung Neoplasms 2Graft vs Host Disease 2Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Polycythemia Vera 1Neutropenia 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Idarubicin × Clear all
NCT03727633 2026-03-31

LIDA-BII

University Hospital, Montpellier

Phase 2 Terminated
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡